Mavenir in Collaboration with Intel Delivers Optimised Performance and Power Efficiency for 4G and 5G Open vRAN Solution
24.2.2024 14:37:00 EET | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces availability of its cutting-edge Open vRAN solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost – delivering a cloud-native, high-performance and energy-efficient solution for latency-sensitive and compute-intensive mobile network applications. The move to Intel’s recent processors for vRAN marks the latest solution optimisation for Mavenir, which has driven Open RAN momentum through three generations of Intel Xeon Scalable processors.
Mavenir's Open vRAN solution, powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost, offers an exceptional suite of performance, functionality, and integrated artificial intelligence (AI) and machine learning (ML) application for the next generation 4G and 5G networks. Mavenir has built a close and long-standing technology collaboration with Intel, and the adoption of Intel’s processors enables the development of more efficient and cost-effective RANs. These optimisations are being achieved through the availability of more processing power with higher capacity, resulting in reduction of number of cores or servers needed per cell site.
Mavenir's Open vRAN solution comprises the virtualised distributed Unit (vDU) and the centralised unit (vCU), supporting all mobile network generations (2G, 4G, 5G) and providing a complete baseband unit (BBU) functionality. The solution is cloud-native and easily deployable on Intel architecture-based private, hybrid, or public clouds. The Mavenir vDU incorporates Intel’s FlexRAN reference software, which utilises modular, virtualised control functions across well-defined interfaces that allow flexible and programmable control of the layer 1 wireless infrastructure.
The fully integrated vRAN acceleration feature of 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost eliminates the need for an external acceleration card and delivers up to 2x capacity increase with an additional 20% power savings1 versus the previous generation processor for applications like massive MIMO (mMIMO). This fully integrated solution allows Mobile Network Operators (MNOs) to deploy cloud-native, energy-efficient and AI-driven RAN solutions at a significantly lower cost.
Mavenir's pioneering Open vRAN solution has driven significant industry progress for Open RAN technology, and made Open RAN a mainstream consideration for all operators expanding their 4G and 5G networks, whether building new networks from scratch or upgrading existing ones. The combination sets the stage for more significant advances in next-generation O-RANs including dramatic energy savings, RAN slice assurance, AI/ML-powered SLAs, expanded RAN capacity, and optimised functionality splits.
BG Kumar, President, Access Networks, Platforms and Digital Enablement for Mavenir commented: “Mavenir values our ongoing collaboration with Intel, which is leading the industry in driving forward high-performance and sustainable Open vRAN solutions for 4G and 5G networks. Mavenir’s integrated solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost optimises the Open vRAN solution offerings even further– giving CSPs worldwide the ability to deploy cloud-native, energy-efficient, and cost-effective AI/ML powered RAN infrastructure built on world-class technology.”
Cristina Rodriguez, Vice President and General Manager, Wireless Access Networking Division at Intel said: “Operators’ journey to design and deploy new networks drives a key set of technology needs and challenges to be addressed. Mavenir’s solution leverages the best features of Intel’s 4th Gen Intel Xeon platform to provide operators a flexible solution with advanced functionalities to meet the diverse needs of both greenfield and brownfield operators.”
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realise the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
____________________________
1 For workloads and configurations visit www.Intel.com/PerformanceIndex. Results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223458554/en/
Contact information
Mavenir PR Contact:
Emmanuela Spiteri
PR@mavenir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom